All In Biotech

Drug Trial Radar · NCT06535893

Sustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast Cancer

Sustainable and Efficient Platform of New Therapeutic Development for Early Breast Cancer (S-FACT)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jul 30, 2024

Primary completion

Jun 30, 2027

Study completion Jun 30, 2040

Sponsor

Lead sponsor
Nagoya City UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Japan Clinical Oncology Group
First posted
Aug 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Randomized phase II trial targeting early-stage breast cancer (stage II-III) applicable to preoperative chemotherapy (NAC), comparing standard treatment with multiple experimental treatments.

Conditions

  • Breast Cancer

Interventions

  • TNDrug

    Carboplatin + paclitaxel + pembrolizumab followed by doxorubicin + cyclophosphamide + pembrolizumab

  • TN-1Drug

    Carboplatin + paclitaxel + pembrolizumab followed by niraparib + pembrolizumab Niraparib Pembrolizumab AC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. pathological complete response (pCR)Time frame: Baseline to surgery
  2. ctDNA clearance rateTime frame: Before Neoadjuvant chemotherapy to surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nagoya City University

    Nagoya, Aichi-ken, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.